Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles by Arthritis & Rheumatology

Lenabasum for Diffuse Cutaneous Systemic Sclerosis

Arthritis & Rheumatology  |  July 27, 2020

In a new study, Spiera et al. assessed the safety and efficacy of lenabasum, a synthetic, orally administered agonist of cannabinoid receptor 2 that modulates the endocannabinoid system to activate the resolution phase of innate immune responses, in diffuse cutaneous systemic sclerosis…

Biosimilar Prescribing Habits in the VA & Academic Settings

Arthritis & Rheumatology  |  June 29, 2020

In a new study, Baker et al. examined reference product and biosimilar orders, comparing data from a Veterans Affairs Medical Center (VAMC) to those from an academic medical center…

Are ANAs More Prevalent in the U.S. Now Than in the Past?

Arthritis & Rheumatology  |  May 28, 2020

According to a new study, the prevalence of anti-nuclear antibodies (ANAs), the most common biomarker of autoimmunity in the U.S., has increased considerably in recent years among adolescents aged 12–19 years, in both sexes (especially in men), older adults (age ≥50 years) and non-Hispanic whites…

Researchers Discuss Viability of Rheumatology Education During the COVID‐19 Pandemic

Arthritis & Rheumatology  |  May 15, 2020

In a matter of weeks, the COVID‑19 crisis has totally upended clinical medicine and the practice of rheumatology. Our old ways of seeing patients in person, precepting fellows in clinic or on the consult service, and leading in-person interactive teaching rounds are gone for now and possibly for good. But how can we replace these…

9/11 Survivors at Increased Risk for Autoimmune Disease

Arthritis & Rheumatology  |  April 30, 2020

Miller-Archie et al. set out to determine whether dust exposure and PTSD are associated with an increased risk of systemic autoimmune disease in a 9/11-exposed cohort not included in previous studies of members of the Fire Department of New York and whether this association differs between 9/11 responders and community members.

A Combined Immunosuppressive Regimen for ILD MDA5-Positive Dermatomyositis

Arthritis & Rheumatology  |  February 27, 2020

Interstitial lung disease accompanied by anti-melanoma differentiation-associated gene 5 positive dermatomyositis is often rapidly progressive and associated with poor prognosis. In this study, a combined immunosuppressive regimen of high-dose glucocorticoids, tacrolimus and intravenous cyclophosphamide proved more effective than treatment with high-dose glucocorticoids and stepwise addition of an immunosuppressant in a historical control group.

New ACR/EULAR IgG4 Classification Criteria Introduced

Arthritis & Rheumatology  |  January 2, 2020

Immunoglobulin G4-related disease (IgG4-RD) can cause fibroinflammatory lesions in nearly any organ. Correlation among clinical, serologic, radiologic and pathologic data is required for diagnosis. ACR/EULAR classification criteria for IgG4-RD have now been developed and validated in a large cohort of patients…

Potential Link Between OA & Gout

Arthritis & Rheumatology  |  December 2, 2019

Monosodium urate (MSU) crystal formation, deposition and gout flares frequently affect joints that have been damaged or are affected by osteoarthritis. These researchers examined the effects of human cartilage homogenates on MSU crystallization and MSU crystal-induced inflammation…

Cryoglobulins: Quantified & Characterized

Arthritis & Rheumatology  |  October 31, 2019

This study used up-to-date techniques to perform an exhaustive immunologic description of cryoglobulins with regard to characterization and quantification…

What Causes Knee, Hip & Hand Osteoarthritis

Arthritis & Rheumatology  |  September 25, 2019

Funck-Brentano et al. hypothesized that causal associations for osteoarthritis (OA) may differ by site, and they undertook this study to identify causal risk factors of knee, hip and hand OA.

  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 12
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences